Nyt fra tidsskrifterne
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
47 ud af 47 tidsskrifter valgt, søgeord (omicron) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
182 emner vises.
Clinical Infectious Diseases, 21.02.2024
Tilføjet 21.02.2024
To the Editor— From early in the coronavirus disease 2019 (COVID-19) pandemic, it became evident that the natural disease course undergoes different stages, from an initial mild viral phase to a more severe inflammatory phase and ultimately to a critical thromboinflammatory phase, often corresponding to acute respiratory distress syndrome in hospitalized patients. Most treatment guidelines have kept these disease stages in their algorithms, generally recommending early antiviral treatment for the mild to moderate disease, and immunomodulatory treatment for severe to critical disease [1]. However, as the virus has changed from pre-omicron to omicron variants, and the target population from immunologically naive to mostly vaccinated or recovered, these phases are less distinct [2].
Læs mere Tjek på PubMedSien Ombelet, Diego Castanares‐Zapatero, Fabian Desimpel, Frank Hulstaert, Sabine Stordeur, Dominique Roberfroid
Journal of Medical Virology, 21.02.2024
Tilføjet 21.02.2024
BMC Infectious Diseases, 21.02.2024
Tilføjet 21.02.2024
Abstract Background In November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was detected in South Africa and subsequently rapidly spread around the world. Despite the reduced severity of the omicron variants, many patients become severely ill after infection and undergo invasive mechanical ventilation, but there are few reports on their background and prognosis throughout all variant periods. This study aimed to evaluate risk factors affecting patients requiring invasive mechanical ventilation with each variant of COVID-19 pandemic in Japan from nonvariants to omicron variants. Method This retrospective observational study was conducted at the Department of Emergency and Critical Care Medicine, Kansai Medical University Hospital and Kansai Medical University Medical Center, Osaka, Japan, from March 2020 to March 2023. Eligible patients were those who underwent invasive ventilation for COVID-19 pneumonia. We set the primary endpoint as in-hospital mortality. Multivariable logistic regression analysis adjusted for clinically important variables was performed to evaluate the clinical outcomes. Results We included 377 patients: 118 in the Nonvariant group, 154 in the Alpha group, 42 in the Delta group, and 63 patients in the Omicron group. Mortality rates for each group were 23.7% for the Nonvariant group, 12.3% for the Alpha group, 7.1% for the Delta group, and 30.5% for the Omicron group. Patient age was significantly associated with increased mortality (adjusted odds ratio [AOR]: 1.097; 95% confidence interval [CI]: 1.057–0.138, P
Læs mere Tjek på PubMedBMC Infectious Diseases, 20.02.2024
Tilføjet 20.02.2024
Abstract The coronavirus disease of 2019 (COVID-19) resulted from an infection by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) which is the main cause of acute respiratory distress syndrome (ARDS) in global population from 2019 on. It may contribute to higher rate of death among the patients with immunodeficiency based on recent reports. In addition, Good syndrome (GS) as a result of thymoma removal might cause in some long-lasting microbial infections. We described clinical aspects and viral mutations on a case of GS suffering from COVID-19. A 46-year-old man with fever, common respiratory disease symptoms and positive COVID-19 polymerase chain reaction (PCR) test, with the history of thymoma removal surgery was admitted to Masih Daneshvari Hospital, Tehran, Iran. Lung radiographs and oxygen saturation measurement disclosed considerable implication resulted in application of several anti-microbial medication. The delta variant (B.1.617.2 (21 J Clade)) was the strain isolated from the patient by sequencing methods done by the COVID-19 National Reference Laboratory (CNRL), Pasteur Institute of Iran, while the dominant strain circulated mostly among population was Omicron (B.1.1.529) at the time of sampling. Unfortunately, the patient had passed away a month later by sudden respiratory failure progressed in refractory septic shock. Despite the fact that opportunistic infections may lead the GS patients to a major health problematic condition, unusual persistent of infections such as non-dominant variant of SARS-Cov-2 could be observed through the disease timeline. Therefore, a fully screening of thymoma plus intra-host evolution monitoring of SARS-CoV-2 is highly recommended in immunocompromised patients.
Læs mere Tjek på PubMedBMC Infectious Diseases, 17.02.2024
Tilføjet 17.02.2024
Abstract Background Fear of a global public health issue and fresh infection wave in the persistent COVID-19 pandemic has been enflamed by the appearance of the novel variant Omicron BF.7 lineage. Recently, it has been seeing the novel Omicron subtype BF.7 lineage has sprawled exponentially in Hohhot. More than anything, risk stratification is significant to ascertain patients infected with COVID-19 who the most need in-hospital or in-home management. The study intends to understand the clinical severity and epidemiological characteristics of COVID-19 Omicron subvariant BF.7. lineage via gathering and analyzing the cases with Omicron subvariant in Hohhot, Inner Mongolia. Methods Based upon this, we linked variant Omicron BF.7 individual-level information including sex, age, symptom, underlying conditions and vaccination record. Further, we divided the cases into various groups and assessed the severity of patients according to the symptoms of patients with COVID-19. Clinical indicators and data might help to predict disadvantage outcomes and progression among Omicron BF.7 patients. Results In this study, in patients with severe symptoms, some indicators from real world data such as white blood cells, AST, ALT and CRE in patients with Omicron BF.7 in severe symptoms were significantly higher than mild and asymptomatic patients, while some indicators were significantly lower. Conclusions Above results suggested that the indicators were associated with ponderance of clinical symptoms. Our survey emphasized the value of timely investigations of clinical data obtained by systemic study to acquire detailed information.
Læs mere Tjek på PubMedBMC Infectious Diseases, 17.02.2024
Tilføjet 17.02.2024
Abstract Background Omicron has become the dominant variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since first reported in November 2021. From the initially detected Wuhan lineage, sublineages BA.2, BA.4, BA.5, BQ, XAG, and XBB have emerged over time and are dominant in many countries. Therefore, the aim is to evaluate which variants are circulating and the clinical characteristics of inpatients infected with the Omicron variant. Methods This retrospective cohort study selected hospitalized patients admitted with respiratory symptoms to a hospital in the state of Rio Grande do Sul, Brazil, between June and July 2022. SARS-CoV-2 results were analyzed together with clinical outcomes and vaccination status. A viral genome library was prepared and forwarded to the Illumina MiSeq Platform for sequencing. Results In total, 37 genomes were sequenced. Concerning the Omicron sublineages, our study detected: BA.1 (21 K), BA.2 (21 L), BA.4 (22A), BA.5 (22B), BA.2.12.1 (22C), BQ.1 (22E), XBB (22F), and XAG recombinant. Omicron BA.5 (30%), BA.2 (19%), and BQ.1 (19%) were the most frequent sublineages, respectively. In total, 38% of patients present hypertension, and the most common symptoms were coughing (62%). Analyzing the COVID-19 vaccination, 30% of patients were fully vaccinated, 49% had a partial vaccination status, and 21% were unvaccinated (no dose). Conclusions BA.5 was the most prevalent sublineage in our study and surpassed the predominance of BA.2, as reported by the national genomic surveillance program. BQ.1 was diagnosed earlier in this study than it was officially reported in the state. Current data have demonstrated that the Omicron variant causes less severe infections, with the high rate of transmissibility and mutational landscape causing the rapid emergence of new sublineages.
Læs mere Tjek på PubMedInfection, 16.02.2024
Tilføjet 16.02.2024
Abstract Purpose Anti SARS-CoV-2 vaccination initially showed high effectiveness in preventing COVID-19. However, after the surge of variants of concern, the effectiveness dropped. Several studies investigated if this was related to the decrease of the humoral response over time; however, this issue is still unclear. The aim of this study was to understand whether SARS-CoV-2 anti-S IgG levels can be used to predict breakthrough infection risk and define the timing for further booster doses administration. Method Within the framework of the ORCHESTRA Project, over 20,000 health workers from 11 European centers were enrolled since December 2020. We performed two Cox proportional hazards survival analyses regarding pre-Omicron (from January to July 2021) and Omicron (December 2021–May 2022) periods. The serological response was classified as high (above the 75th percentile), medium (25th-75th), or low (
Læs mere Tjek på PubMedBMC Infectious Diseases, 16.02.2024
Tilføjet 16.02.2024
Abstract Background Fear of a global public health issue and fresh infection wave in the persistent COVID-19 pandemic has been enflamed by the appearance of the novel variant Omicron BF.7 lineage. Recently, it has been seeing the novel Omicron subtype BF.7 lineage has sprawled exponentially in Hohhot. More than anything, risk stratification is significant to ascertain patients infected with COVID-19 who the most need in-hospital or in-home management. The study intends to understand the clinical severity and epidemiological characteristics of COVID-19 Omicron subvariant BF.7. lineage via gathering and analyzing the cases with Omicron subvariant in Hohhot, Inner Mongolia. Methods Based upon this, we linked variant Omicron BF.7 individual-level information including sex, age, symptom, underlying conditions and vaccination record. Further, we divided the cases into various groups and assessed the severity of patients according to the symptoms of patients with COVID-19. Clinical indicators and data might help to predict disadvantage outcomes and progression among Omicron BF.7 patients. Results In this study, in patients with severe symptoms, some indicators from real world data such as white blood cells, AST, ALT and CRE in patients with Omicron BF.7 in severe symptoms were significantly higher than mild and asymptomatic patients, while some indicators were significantly lower. Conclusions Above results suggested that the indicators were associated with ponderance of clinical symptoms. Our survey emphasized the value of timely investigations of clinical data obtained by systemic study to acquire detailed information.
Læs mere Tjek på PubMedBMC Infectious Diseases, 14.02.2024
Tilføjet 14.02.2024
Abstract Background Omicron has become the dominant variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since first reported in November 2021. From the initially detected Wuhan lineage, sublineages BA.2, BA.4, BA.5, BQ, XAG, and XBB have emerged over time and are dominant in many countries. Therefore, the aim is to evaluate which variants are circulating and the clinical characteristics of inpatients infected with the Omicron variant. Methods This retrospective cohort study selected hospitalized patients admitted with respiratory symptoms to a hospital in the state of Rio Grande do Sul, Brazil, between June and July 2022. SARS-CoV-2 results were analyzed together with clinical outcomes and vaccination status. A viral genome library was prepared and forwarded to the Illumina MiSeq Platform for sequencing. Results In total, 37 genomes were sequenced. Concerning the Omicron sublineages, our study detected: BA.1 (21 K), BA.2 (21 L), BA.4 (22A), BA.5 (22B), BA.2.12.1 (22C), BQ.1 (22E), XBB (22F), and XAG recombinant. Omicron BA.5 (30%), BA.2 (19%), and BQ.1 (19%) were the most frequent sublineages, respectively. In total, 38% of patients present hypertension, and the most common symptoms were coughing (62%). Analyzing the COVID-19 vaccination, 30% of patients were fully vaccinated, 49% had a partial vaccination status, and 21% were unvaccinated (no dose). Conclusions BA.5 was the most prevalent sublineage in our study and surpassed the predominance of BA.2, as reported by the national genomic surveillance program. BQ.1 was diagnosed earlier in this study than it was officially reported in the state. Current data have demonstrated that the Omicron variant causes less severe infections, with the high rate of transmissibility and mutational landscape causing the rapid emergence of new sublineages.
Læs mere Tjek på PubMedAlba EscaleraManon LaporteSam TurnerUmut KarakusAna S. Gonzalez-ReicheAdriana van de GuchteKeith FarrugiaZain KhalilHarm van BakelDerek SmithAdolfo García-SastreTeresa Aydilloa Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USAb Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAc Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USAd Center for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UKe Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USAf Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAg Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USAh Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USAi The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Emerg Microbes Infect, 13.02.2024
Tilføjet 13.02.2024
Haoting Zhan, Yuchen Xie, Yongmei Liu, Linlin Cheng, Yi Xu, Xiaojing Qu, Chen Li, Xinru Guo, Haolong Li, Yuling Wang, Erhei Dai, Lijing Wang, Huixia Gao, Yongzhe Li
Journal of Medical Virology, 13.02.2024
Tilføjet 13.02.2024
Journal of Infectious Diseases, 13.02.2024
Tilføjet 13.02.2024
Abstract Background Monovalent Omicron XBB.1.5-containing vaccines were approved for Coronavirus disease 2019 (COVID-19) 2023-2024 immunizations.Methods This ongoing, open-label, phase 2/3 study evaluated mRNA-1273.815-monovalent (50-µg Omicron XBB.1.5-spike mRNA) and mRNA-1273.231-bivalent (25-µg each Omicron XBB.1.5- and BA.4/BA.5-spike mRNAs))vaccines, administered as 5th doses to adults who previously received a primary series, a 3rd dose of an original mRNA COVID-19 vaccine, and a 4th dose of an Omicron BA.4/BA.5 bivalent vaccine. Interim safety and immunogenicity results 29 days post-vaccination are reported.Results Participants (randomized 1:1) received 50-µg mRNA-1273.815(n=50) or mRNA-1273.231(n=51); median (interquartile range) months from the prior BA.4/BA.5-bivalent dose were 8.2 (8.1-8.3) and 8.3 (8.1-8.4), respectively. Neutralizing antibody (nAb) increased from pre-booster levels against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants tested. Day 29 nAb fold-increases from pre-booster levels were numerically higher against XBB.1.5, XBB.1.16, EG.5.1, BA.2.86, and JN.1 than BA.4/BA.5, BQ.1.1 and D614G. The monovalent vaccine also cross-neutralized FL.1.5.1, EG.5.1, BA.2.86, HK.3.1, HV.1 and JN.1 variants in a participant (n=20) subset, 15 days post-vaccination. Reactogenicity was similar to previously reported mRNA-1273 original and bivalent vaccines.Conclusions XBB.1.5-containing mRNA-1273 vaccines elicit robust, diverse nAb responses against more recent SARS-CoV-2 variants including JN.1, supporting the XBB.1.5-spike sequence selection for the 2023-2024 COVID-19 vaccine update.
Læs mere Tjek på PubMedQi Tang, Xubiao Xie, Longkai Peng, Linxin Yang, Yubin Chen, Shaojie Yu
International Journal of Infectious Diseases, 13.02.2024
Tilføjet 13.02.2024
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia poses significant challenges to global health systems, particularly in severe and critical cases [1]. Coronavirus disease 2019 (COVID-19) patients are at risk of diffuse alveolar damage (DAD), acute respiratory distress syndrome (ARDS), and multi-organ failure, which are the main causes of death [2, 3]. Renal transplant recipients are particularly vulnerable to severe or critical COVID-19 illness, and mortality rates are high in this patient group [4-7].
Læs mere Tjek på PubMedJohn Van Dusen, Haley LeBlanc, Nicholas Nastasi, Jenny Panescu, Austin Shamblin, Jacob W. Smith, Michael G. Sovic, Amanda Williams, Mikkel B. M. Quam, Seth Faith, Karen C. Dannemiller
PLoS One Infectious Diseases, 10.02.2024
Tilføjet 10.02.2024
by John Van Dusen, Haley LeBlanc, Nicholas Nastasi, Jenny Panescu, Austin Shamblin, Jacob W. Smith, Michael G. Sovic, Amanda Williams, Mikkel B. M. Quam, Seth Faith, Karen C. Dannemiller Environmental surveillance of pathogens underlying infectious disease is critical to ensure public health. Recent efforts to track SARS-CoV-2 have utilized wastewater sampling to infer community trends in viral abundance and variant composition. Indoor dust has also been used for building-level inferences, though to date no sequencing data providing variant-scale resolution have been reported from dust samples, and strategies to monitor circulating variants in dust are needed to help inform public health decisions. In this study, we demonstrate that SARS-CoV-2 lineages can be detected and sequenced from indoor bulk dust samples. We collected 93 vacuum bags from April 2021 to March 2022 from buildings on The Ohio State University’s (OSU) Columbus campus, and the dust was used to develop and apply an amplicon-based whole-genome sequencing protocol to identify the variants present and estimate their relative abundances. Three variants of concern were detected in the dust: Alpha, Delta, and Omicron. Alpha was found in our earliest sample in April 2021 with an estimated frequency of 100%. Delta was the primary variant present from October of 2021 to January 2022, with an average estimated frequency of 91% (±1.3%). Omicron became the primary variant in January 2022 and was the dominant strain in circulation through March with an estimated frequency of 87% (±3.2%). The detection of these variants on OSU’s campus correlates with the circulation of these variants in the surrounding population (Delta p
Læs mere Tjek på PubMedSivaprakasam T. Selvavinayagam, Suvaiyarasan Suvaithenamudhan, Yean K. Yong, Kannan Hemashree, Manivannan Rajeshkumar, Anandhazhvar Kumaresan, Parthiban Arthydevi, Meganathan Kannan, Natarajan Gopalan, Ramachandran Vignesh, Amudhan Murugesan, Munusamy P. Sivasankaran, Sathish Sankar, Narayanaiah Cheedarla, Abdul R. Anshad, Sakthivel Govindaraj, Ying Zhang, Hong Y. Tan, Marie Larsson, Shanmugam Saravanan, Pachamuthu Balakrishnan, Langeswaran Kulanthaivel, Kamalendra Singh, Narcisse Joseph, Vijayakumar Velu, Siddappa N. Byrareddy, Esaki M. Shankar, Sivadoss Raju
Journal of Medical Virology, 9.02.2024
Tilføjet 9.02.2024
Infection, 9.02.2024
Tilføjet 9.02.2024
Abstract Purpose Anti SARS-CoV-2 vaccination initially showed high effectiveness in preventing COVID-19. However, after the surge of variants of concern, the effectiveness dropped. Several studies investigated if this was related to the decrease of the humoral response over time; however, this issue is still unclear. The aim of this study was to understand whether SARS-CoV-2 anti-S IgG levels can be used to predict breakthrough infection risk and define the timing for further booster doses administration. Method Within the framework of the ORCHESTRA Project, over 20,000 health workers from 11 European centers were enrolled since December 2020. We performed two Cox proportional hazards survival analyses regarding pre-Omicron (from January to July 2021) and Omicron (December 2021–May 2022) periods. The serological response was classified as high (above the 75th percentile), medium (25th-75th), or low (
Læs mere Tjek på PubMedJianpeng CaiHaocheng ZhangKun ZhuFeng ZhuYan WangSen WangFaren XieMeng ZhangLili RuiShuhong LiKe LinQuanlin XueGuanmin YuanHongyu WangYi ZhangZhangfan FuJieyu SongYanliang ZhangJingwen AiWenhong Zhanga Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, National Medical Center for Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of Chinab Department of Respiratory and Critical Care Medicine, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi Fifth People's Hospital, Wuxi, People’s Republic of Chinac Department of Infectious Diseases, The Sixth People’s Hospital of Shenyang, Shenyang, People’s Republic of Chinad Department of Infectious Diseases, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing, People’s Republic of Chinae Nanjing Research Center for Infectious Diseases of Integrated Traditional Chinese and Western Medicine, Nanjing, People’s Republic of Chinaf Shanghai Huashen Institute of Microbes and Infections, Shanghai, People’s Republic of China
Emerg Microbes Infect, 7.02.2024
Tilføjet 7.02.2024
Kyungmin Huh, Young-Eun Kim, Gi Hwan Bae, Jong Youn Moon, Ji-Man Kang, Jacob Lee, Jang-Whan Bae, Kyong Ran Peck, Jaehun Jung
Clinical Microbiology and Infection, 6.02.2024
Tilføjet 6.02.2024
To assess the association of primary and third doses of vaccination with the risk of post-acute sequelae of COVID-19.
Læs mere Tjek på PubMedPan Liu, Zixuan Xing, Xiaokang Peng, Mengyi Zhang, Chang Shu, Ce Wang, Ruina Li, Li Tang, Huijing Wei, Xiaoshan Ran, Sikai Qiu, Ning Gao, Yee Hui Yeo, Xiaoguai Liu, Fanpu Ji
Journal of Medical Virology, 3.02.2024
Tilføjet 3.02.2024
Stephan Gehring, Frank Kowalzik, Omar Okasha, Tobias Engelmann, Daniel Schreiner, Christian Jensen, Aline Mähringer-Kunz, Wendy Hartig-Merkel, Thao Mai Phuong Tran, Cornelia Oostvogels, Thomas Verstraeten
PLoS One Infectious Diseases, 31.01.2024
Tilføjet 31.01.2024
by Stephan Gehring, Frank Kowalzik, Omar Okasha, Tobias Engelmann, Daniel Schreiner, Christian Jensen, Aline Mähringer-Kunz, Wendy Hartig-Merkel, Thao Mai Phuong Tran, Cornelia Oostvogels, Thomas Verstraeten We assessed the seroepidemiology of SARS-CoV-2 infection and the incidence of coronavirus disease 2019 (COVID-19) before and during the rollout of COVID-19 vaccines, in a prospective observational cohort study on healthcare workers (HCWs) in a large tertiary hospital in Mainz, Germany. Antibody status was assessed during six visits between September 2020 and February 2022. Self-reported symptoms were collected using a smartphone application; symptomatic HCWs were tested using real-time polymerase chain reaction (RT-PCR) assays for SARS-CoV-2. Rates of virologically confirmed and severe COVID-19 were estimated using the U.S. Food and Drug Administration (FDA) and Coalition for Epidemic Preparedness Innovations (CEPI) case definitions, respectively, and were contrasted to background community transmission and circulating SARS-CoV-2 variants. A total of 3665 HCWs were enrolled (mean follow-up time: 18 months); 97 met the FDA definition of virologically confirmed COVID-19 (incidence rate (IR) 2.3/1000 person-months (PMs), one severe case). Most cases reported ≥2 symptoms, commonly, cough and anosmia or ageusia. Overall, 263 individuals seroconverted (IR 6.6/1000 PMs—2.9 times the estimated IR of COVID-19), indicating many cases were missed, either due to asymptomatic infections or to an atypical presentation of symptoms. A triphasic trend in anti-SARS-CoV-2 seroprevalence and seroconversion was observed, with an initial increase following the rollout of COVID-19 vaccines, a two-fold decline six months later, and finally a six-fold increase by the end of the study when Omicron was the dominant circulating variant. Despite the increase in infection rates at the end of the study due to the circulation of the Omicron variant, the infection and disease rates observed were lower than the published estimates in HCWs and rates in the general local population. Preferential vaccination of HCWs and the strict monitoring program for SARS-CoV-2 infection are the most likely reasons for the successful control of COVID-19 in this high-risk population.
Læs mere Tjek på PubMedBMC Infectious Diseases, 30.01.2024
Tilføjet 30.01.2024
Abstract Background The spread of SARS-CoV-2 has been studied at unprecedented levels worldwide. In jurisdictions where molecular analysis was performed on large scales, the emergence and competition of numerous SARS-CoV-2lineages have been observed in near real-time. Lineage identification, traditionally performed from clinical samples, can also be determined by sampling wastewater from sewersheds serving populations of interest. Variants of concern (VOCs) and SARS-CoV-2 lineages associated with increased transmissibility and/or severity are of particular interest. Method Here, we consider clinical and wastewater data sources to assess the emergence and spread of VOCs in Canada retrospectively. Results We show that, overall, wastewater-based VOC identification provides similar insights to the surveillance based on clinical samples. Based on clinical data, we observed synchrony in VOC introduction as well as similar emergence speeds across most Canadian provinces despite the large geographical size of the country and differences in provincial public health measures. Conclusion In particular, it took approximately four months for VOC Alpha and Delta to contribute to half of the incidence. In contrast, VOC Omicron achieved the same contribution in less than one month. This study provides significant benchmarks to enhance planning for future VOCs, and to some extent for future pandemics caused by other pathogens, by quantifying the rate of SARS-CoV-2 VOCs invasion in Canada.
Læs mere Tjek på PubMedInfection, 25.01.2024
Tilføjet 25.01.2024
Abstract Purpose Emerging SARS-CoV-2 variants have impacted the in vitro activity of sotrovimab, with variable fold changes in neutralization potency for the Omicron BA.2 sublineage and onward. The correlation between reduced in vitro activity and clinical efficacy outcomes is unknown. A systematic literature review (SLR) evaluated the effectiveness of sotrovimab on severe clinical outcomes during Omicron BA.2 predominance. Methods Electronic databases were searched for peer-reviewed journals, preprint articles, and conference abstracts published from January 1–November 3, 2022. Results Five studies were included, which displayed heterogeneity in study design and population. Two UK studies had large samples of patients during BA.2 predominance: one demonstrated clinical effectiveness vs molnupiravir during BA.1 (adjusted hazard ratio [aHR] 0.54, 95% CI 0.33–0.88; p = 0.014) and BA.2 (aHR 0.44, 95% CI 0.27–0.71; p = 0.001); the other reported no difference in the clinical outcomes of sotrovimab-treated patients when directly comparing sequencing-confirmed BA.1 and BA.2 cases (HR 1.17, 95% CI 0.74–1.86). One US study showed a lower risk of 30-day all-cause hospitalization/mortality for sotrovimab compared with no treatment during the BA.2 surge in March (adjusted relative risk [aRR] 0.41, 95% CI 0.27–0.62) and April 2022 (aRR 0.54, 95% CI 0.08–3.54). Two studies from Italy and Qatar reported low progression rates but were either single-arm descriptive or not sufficiently powered to draw conclusions on the effectiveness of sotrovimab. Conclusion This SLR showed that the effectiveness of sotrovimab was maintained against Omicron BA.2 in both ecological and sequencing-confirmed studies, by demonstrating low/comparable clinical outcomes between BA.1 and BA.2 periods or comparing against an active/untreated comparator.
Læs mere Tjek på PubMedBMC Infectious Diseases, 24.01.2024
Tilføjet 24.01.2024
Abstract Purpose We aimed to analyze the clinical features of COVID-19-associated pulmonary aspergillosis (CAPA) during the SARS-CoV-2 Omicron variant pandemic and to reveal the risk factors for CAPA and death. Methods A retrospective cohort study was conducted on 168 CAPA patients from December 8, 2022 to January 31, 2023. 168 COVID-19 patients without secondary fungal infection during this period were matched 1:1 using propensity score matching as controls. Results The incidence of CAPA was 3.8% (168/4421). Compared with patients without fungal infection, CAPA patients had a higher mortality (43.5% vs. 10.1%, P
Læs mere Tjek på PubMedFynn Atzler, Florian Dahms, Gregor Paul, Stojan Perisic
Journal of Medical Virology, 19.01.2024
Tilføjet 19.01.2024
Erlin Wang, Qiao‐Jiang Yang, Xiang‐Xiong Xu, Qing‐Cui Zou, Yanghaopeng Long, Guanqin Ma, Zhong‐Hua Deng, Jie‐Bin Zhao, Ming‐Hua Li, Jianxiong Zeng
Journal of Medical Virology, 19.01.2024
Tilføjet 19.01.2024
Clinical Infectious Diseases, 18.01.2024
Tilføjet 18.01.2024
Abstract Background Infection prevention (IP) measures are designed to mitigate the transmission of pathogens in healthcare. Using large-scale viral genomic and social network analyses, we determined if IP measures used during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic were adequate in protecting healthcare workers (HCWs) and patients from acquiring SARS-CoV-2.Methods We performed retrospective cross-sectional analyses of viral genomics from all available SARS-CoV-2 viral samples collected at UC San Diego Health and social network analysis using the electronic medical record to derive temporospatial overlap of infections among related viromes and supplemented with contact tracing data. The outcome measure was any instance of healthcare transmission, defined as cases with closely related viral genomes and epidemiological connection within the healthcare setting during the infection window. Between November 2020 through January 2022, 12 933 viral genomes were obtained from 35 666 patients and HCWs.Results Among 5112 SARS-CoV-2 viral samples sequenced from the second and third waves of SARS-CoV-2 (pre-Omicron), 291 pairs were derived from persons with a plausible healthcare overlap. Of these, 34 pairs (12%) were phylogenetically linked: 19 attributable to household and 14 to healthcare transmission. During the Omicron wave, 2106 contact pairs among 7821 sequences resulted in 120 (6%) related pairs among 32 clusters, of which 10 were consistent with healthcare transmission. Transmission was more likely to occur in shared spaces in the older hospital compared with the newer hospital (2.54 vs 0.63 transmission events per 1000 admissions, P < .001).Conclusions IP strategies were effective at identifying and preventing healthcare SARS-CoV-2 transmission.
Læs mere Tjek på PubMedHarold MarcotteYunlong CaoFanglei ZuoLuca SimonelliJosè Camilla SammartinoMattia PedottiRui SunIrene CassanitiMarie HagbomAntonio PirallaJinxuan YangLikun DuElena PercivalleFederico BertoglioMaren SchubertHassan AbolhassaniNatalia SherinaConcetta GuerraStephan BorteNima RezaeiMakiko Kumagai-BraeschYintong XueChen SuQihong YanPing HeCaroline GrönwallLars KlareskogLuigi CalzolaiAndrea CavalliQiao WangDavide F. RobbianiMichael HustZhengli ShiLiqiang FengLennart SvenssonLing ChenLinlin BaoFausto BaldantiJunyu XiaoChuan QinLennart HammarströmXinglou YangLuca VaraniXiaoliang Sunney XieQiang Pan-HammarströmaDivision of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm 17165, SwedenbChangping Laboratory, Beijing 102206, People’s Republic of ChinacSchool of Life Sciences, Biomedical Pioneering Innovation Center, Peking University, Beijing 100871, People’s Republic of ChinadInstitute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona 6500, SwitzerlandeMicrobiology and Virology Department, Fondazione Istituto di ricovero e cura a carattere scientifico (IRCCS) Policlinico San Matteo, Pavia 27100, ItalyfDivision of Molecular Medicine and Virology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping 58185, SwedengYunnan Key Laboratory of Biodiversity Information, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650023, People’s Republic of ChinahDepartment of Medical Biotechnology, Institute of Biochemistry, Biotechnology and Bioinformatics, Technische Universität Braunschweig, Braunschweig 38106, GermanyiDepartment of Laboratory Medicine, Hospital St. Georg, Leipzig 04129, GermanyjImmunoDeficiencyCenter Leipzig, Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiency Diseases, Hospital St. Georg, Leipzig 04129, GermanykResearch Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran 14194, IranlDivision of Transplantation Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm 14186, SwedenmDepartment of Immunology, Peking University Health Science Center, Beijing 100191, People’s Republic of ChinanState Key Laboratory of Protein and Plant Gene Research, School of Life Sciences, Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, People’s Republic of ChinaoState Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, People’s Republic of ChinapDivision of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm 17176, SwedenqRheumatology Unit, Karolinska University Hospital, Stockholm 17176, SwedenrEuropean Commission, Joint Research Centre, Ispra 21027, ItalysKey Laboratory of Medical Molecular Virology (Ministry of Education/National Health Commission/Chinese Academy of Medical Sciences), Shanghai Institute of Infectious Disease and Biosecurity, School of Basic Medical Sciences, Fudan University, 200032 Shanghai 200032, People’s Republic of ChinatState Key laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei 430071, People’s Republic of ChinauDivision of Infectious Diseases, Department of Medicine, Karolinska Institute, Stockholm 17177, SwedenvGuangzhou Laboratory, Guangzhou 510005, People’s Republic of ChinawBeijing Key Laboratory for Animal Models of Emerging and Remerging Infectious Diseases, National Health Commission Key Laboratory of Human Disease Comparative Medicine, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medicine Center, Peking Union Medical College, Beijing 100021, People’s Republic of ChinaxNational Center of Technology Innovation for Animal Model, Beijing 102206, People’s Republic of ChinayDepartment of Clinical, Surgical, Diagnostic and Paediatric Sciences, University of Pavia, Pavia 27100, Italy
Proceedings of the National Academy of Sciences, 17.01.2024
Tilføjet 17.01.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 3, January 2024.
Læs mere Tjek på PubMedBMC Infectious Diseases, 15.01.2024
Tilføjet 15.01.2024
Abstract Background The Omicron wave of Coronavirus disease 2019 (COVID-19) remains the dominant strain worldwide. The studies of nutritional status in geriatric people with COVID-19 Omicron variant are limited. Thus, the aim of this study was to investigate the incidence of poor nutritional status among Omicron infected older patients, and to explore the correlation between the nutritional status and the severity of Omicron infection in older patients. Methods This is a retrospective cross-sectional study. According to the clinical symptoms, patients were divided into two groups: mild and moderate to severe. Mini Nutritional Assessment short-form (MNA-SF) was conducted when patients were admitted and poor nutritional status was defined as MNA-SF score of 0–11. The inflammatory markers including neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR) and systemic inflammatory index (SII) were calculated and compared between two groups. Results Total of 324 patients were enrolled, with median [interquartile range (IQR)] age of 73 (17) years. Overall, 241 cases were mild, 83 cases were moderate to severe at the time of diagnosis and that 54.3% of patients had poor nutritional status. Patients with poor nutritional status were found to be older (P
Læs mere Tjek på PubMedBMC Infectious Diseases, 9.01.2024
Tilføjet 9.01.2024
Abstract Background Asymptomatic SARS-CoV-2 testing of hospitalised patients began in April-2020, with twice weekly healthcare worker (HCW) testing introduced in November-2020. Guidance recommending asymptomatic testing was withdrawn in August-2022. Assessing the impact of this decision from data alone is challenging due to concurrent changes in infection prevention and control practices, community transmission rates, and a reduction in ascertainment rate from reduced testing. Computational modelling is an effective tool for estimating the impact of this change. Methods Using a computational model of SARS-CoV-2 transmission in an English hospital we estimate the effectiveness of several asymptomatic testing strategies, namely; (1) Symptomatic testing of patients and HCWs, (2) testing of all patients on admission with/without repeat testing on days 3 and 5–7, and (3) symptomatic testing plus twice weekly asymptomatic HCW testing with 70% compliance. We estimate the number of patient and HCW infections, HCW absences, number of tests, and tests per case averted or absence avoided, with differing community prevalence rates over a 12-week period. Results Testing asymptomatic patients on admission reduces the rate of nosocomial SARS-CoV-2 infection by 8.1–21.5%. Additional testing at days 3 and 5–7 post admission does not significantly reduce infection rates. Twice weekly asymptomatic HCW testing can reduce the proportion of HCWs infected by 1.0-4.4% and monthly absences by 0.4–0.8%. Testing asymptomatic patients repeatedly requires up to 5.5 million patient tests over the period, and twice weekly asymptomatic HCW testing increases the total tests to almost 30 million. The most efficient patient testing strategy (in terms of tests required to prevent a single patient infection) was testing asymptomatic patients on admission across all prevalence levels. The least efficient was repeated testing of patients with twice weekly asymptomatic HCW testing in a low prevalence scenario, and in all other prevalence levels symptomatic patient testing with regular HCW testing was least efficient. Conclusions Testing patients on admission can reduce the rate of nosocomial SARS-CoV-2 infection but there is little benefit of additional post-admission testing. Asymptomatic HCW testing has little incremental benefit for reducing patient cases at low prevalence but has a potential role at higher prevalence or with low community transmission. A full health-economic evaluation is required to determine the cost-effectiveness of these strategies.
Læs mere Tjek på PubMedInfectious Disease Modelling, 9.01.2024
Tilføjet 9.01.2024
Publication date: March 2024 Source: Infectious Disease Modelling, Volume 9, Issue 1 Author(s): Hengcong Liu, Xiangyanyu Xu, Xiaowei Deng, Zexin Hu, Ruijia Sun, Junyi Zou, Jiayi Dong, Qianhui Wu, Xinhua Chen, Lan Yi, Jun Cai, Juanjuan Zhang, Marco Ajelli, Hongjie Yu
Læs mere Tjek på PubMedBMC Infectious Diseases, 8.01.2024
Tilføjet 8.01.2024
Abstract Background and aim Two oral antivirals (Nirmatrelvir- ritonavir and Azvudine) are widely used in China practice during the Omicron wave of the pandemic. However, little evidence regarding the real-world effectiveness of these two oral antivirals in in-hospital patients. We aimed to evaluate the clinical effectiveness of nirmatrelvir-ritonavir versus azvudine among adult hospitalized patients with COVID-19. Methods This retrospective cohort study used data from three Chinese PLA General Hospital medical centres. Hospitalized patients with COVID-19 treated with azvudine or nirmatrelvir-ritonavir from Dec 10, 2022, to February 20, 2023, and did not require invasive ventilation support on admission were eligible for inclusion. Results After exclusions and propensity-score matching, the final analysis included 486 azvudine recipients and 486 nirmatrelvir-ritonavir recipients. By 28 days of initiation of the antivirus treatment, the crude incidence rate of all-cause death was similar in both types of antivirus treatment (nirmatrelvir-ritonavir group 2.8 events 1000 person-days [95% CI, 2.1–3.6] vs azvudine group 3.4 events/1000 person-days [95% CI, 2.6–4.3], P = 0.38). Landmark analysis showed that all-cause death was lower in the nirmatrelvir-ritonavir (3.5%) group than the azvudine (6.8%, P = 0.029) within the initial 10-day admission period, while no significant difference was observed for results between 10 and 28 days follow-up. There was no significant difference between the nirmatrelvir-ritonavir group and the azvudine group in cumulative incidence of the composite disease progression event (8.6% with nirmatrelvir-ritonavir vs. 10.1% with azvudine, HR, 1.22; 95% CI 0.80–1.86, P = 0.43). Conclusion Among patients hospitalized with COVID-19 during the omicron wave in Beijing, similar in-hospital clinical outcomes on 28 days were observed between patients receiving nirmatrelvir-ritonavir and azvudine. However, it is worth noticing that nirmatrelvir-ritonavir appears to hold an advantage over azvudine in reducing early mortality. Further randomized controlled trials are needed to verify the efficacy of those two antivirus medications especially in early treatment.
Læs mere Tjek på PubMedBMC Infectious Diseases, 7.01.2024
Tilføjet 7.01.2024
Abstract Background The aim of the present study was to compare the epidemiological patterns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infections, hospitalizations, deaths, and duration of hospitalization during the fourth, fifth and sixth epidemic waves of coronavirus disease 2019 (COVID-19) in Iran. Methods A multicenter retrospective observational study was conducted on hospitalized patients in four hospitals in the Babol district of northern Iran. The study periods were during the fourth, fifth, and sixth waves of the epidemic in Iran, (March 2021 to March 2022). A total of 13,312 patients with suspected COVID-19 were included. Patient demographics, medical history, length of hospital stay, and clinical outcomes were obtained from the hospital information system. Data on the cycle threshold (Ct) and SARS-CoV2 variant were collected for SARS-CoV2-positive cases. Results The highest number of hospitalized patients was reported during the fifth (Delta) wave (5231; 39.3%), while the lowest number of hospitalized patients was reported during the sixth (Omicron) wave (2143; 16.1%). In total, 6459 (48.5%) out of 13,312 hospitalized patients with suspected COVID-19 had a positive rRT-PCR result. The fifth (Delta) wave had the highest number of SARS-CoV2 rRT-PCR-positive hospitalized patients (3573, 55.3%), while the sixth (Omicron) wave had the lowest number (835, 12.9%). Moreover, 238 (3.7%) patients with laboratory-confirmed COVID-19 died. The hospital mortality rate was 6.8% in the fourth (Alpha) wave, which reduced to 2.7 and 3.5% in the fifth (Delta) and sixth (Omicron) waves, respectively (p
Læs mere Tjek på PubMedPeter Seah Keng Tok, Kong Yeow Kang, Sock Wen Ng, Norazida Ab Rahman, Muhammad Aminul Syahmi, Mohan Dass Pathmanathan, Maheshwara Rao Appannan, Kalaiarasu M. Peariasamy, Sheamini Sivasampu
PLoS One Infectious Diseases, 5.01.2024
Tilføjet 5.01.2024
by Peter Seah Keng Tok, Kong Yeow Kang, Sock Wen Ng, Norazida Ab Rahman, Muhammad Aminul Syahmi, Mohan Dass Pathmanathan, Maheshwara Rao Appannan, Kalaiarasu M. Peariasamy, Sheamini Sivasampu Post COVID-19 condition is an important public health problem as we emerge from the COVID-19 pandemic. In this prospective cohort study, we aimed to determine the prevalence of this condition and assess its associated factors and impact on health-related quality of life in a population setting in Malaysia. Study was conducted from April to June 2022 when the Omicron variant predominated. All individuals testing positive for SARS-CoV-2 infection (RT-PCR, RTK-Ag) were invited for participation. Study questionnaires were delivered via the MySejahtera platform (mobile application). From the total of 44,386 participants who provided responses up to 3-months interval, 1,510 participants (3.4%) fulfilled the post COVID-19 condition criteria. Majority of the affected participants (83.8%, n = 1,265) experienced either cough, fatigue or forgetfulness–the three most common symptoms. Being females, having existing comorbidities, presence of symptoms and requiring hospital admission during the acute illness were associated with higher likelihoods of developing the post COVID-19 condition at 3-months interval. Amongst the 1,510 individuals, one in five had limitations in performing their usual daily activities while at least one in three expressed that their work was affected. Understanding this condition better is essential to guide strategic and responsive plans of action, which may require coordinated multidisciplinary interventions.
Læs mere Tjek på PubMedInfection, 4.01.2024
Tilføjet 4.01.2024
Abstract Background The World Health Organization announced the end of the Coronavirus Disease of 2019 (COVID-19) global health emergency on May 5, 2023. However, the reports from different countries indicate an elevation in the number of COVID-19-related hospitalizations and deaths through the last months. The subvariant XBB.1.5 (Kraken) was the cause of 49.1% of COVID-19 cases by the end of January 2023. Although, the subvariant EG.5 (Eris) has surpassed the XBB.1.5 recently. EG.5 is a close subvariant descending from XBB.1.9.2 subvariant of Omicron. EG.5.1 is a sublineage carrying two crucial spike mutations F456L and Q52H. Up to now, it is not well-established whether its infectivity, severity, and immune evasion have shown any change or not. Also, BA.2.86 another subvariant of Omicron descending from BA.2 bears over 30 mutations which could affect its infectivity and transmissibility. Methods Scopus, PubMed, Google Scholar, and Google were searched with six keywords up to 20 November 2023 and highly reliable research and reports were selected to refer to in this article. Purpose This brief review aims to overview the most reliable data about EG.5 and BA.2.86 based on scientific evidence. Conclusion Based on the currently available data these two new subvariants have similar features with currently circulating variants of Omicron and are less immune evasive than ancestral SARS-CoV-2.
Læs mere Tjek på PubMedClinical Infectious Diseases, 4.01.2024
Tilføjet 4.01.2024
To the Editor—We read with interest the article by Hedberg et al that describes the differences in disease severity and outcomes following infections with the severe acute respiratory syndrome coronavirus 2 Omicron variant, influenza, and respiratory syncytial virus (RSV) among adult outpatients and inpatients [1]. The article provided important information and indicated that the Omicron variant is associated with worse outcomes compared with RSV and influenza. We would like to offer some insights that we believe could further enhance the comprehension and context of the study’s findings.
Læs mere Tjek på PubMedInfection, 4.01.2024
Tilføjet 4.01.2024
Abstract Background The World Health Organization announced the end of the Coronavirus Disease of 2019 (COVID-19) global health emergency on May 5, 2023. However, the reports from different countries indicate an elevation in the number of COVID-19-related hospitalizations and deaths through the last months. The subvariant XBB.1.5 (Kraken) was the cause of 49.1% of COVID-19 cases by the end of January 2023. Although, the subvariant EG.5 (Eris) has surpassed the XBB.1.5 recently. EG.5 is a close subvariant descending from XBB.1.9.2 subvariant of Omicron. EG.5.1 is a sublineage carrying two crucial spike mutations F456L and Q52H. Up to now, it is not well-established whether its infectivity, severity, and immune evasion have shown any change or not. Also, BA.2.86 another subvariant of Omicron descending from BA.2 bears over 30 mutations which could affect its infectivity and transmissibility. Methods Scopus, PubMed, Google Scholar, and Google were searched with six keywords up to 20 November 2023 and highly reliable research and reports were selected to refer to in this article. Purpose This brief review aims to overview the most reliable data about EG.5 and BA.2.86 based on scientific evidence. Conclusion Based on the currently available data these two new subvariants have similar features with currently circulating variants of Omicron and are less immune evasive than ancestral SARS-CoV-2.
Læs mere Tjek på PubMedHui Zhang, Chaolin Huang, Xiaoying Gu, Yeming Wang, Xia Li, Min Liu, Qiongya Wang, Jiuyang Xu, Yimin Wang, Huaping Dai, Dingyu Zhang, Bin Cao
Lancet Respiratory Medicine, 3.01.2024
Tilføjet 3.01.2024
Most long COVID symptoms at 3 years were mild to moderate, with lung function recovering to levels of matched controls. Survivors with long COVID had a higher proportion of participants with re-infection and newly occurring or worse symptoms 3 months after omicron infection than those without long COVID. Re-infection had increased symptom occurrence but not increased reduced daily activity. Although the organ function of survivors of COVID-19 recovered over time, those with severe long COVID symptoms, abnormal organ function, or limited mobility require urgent attention in future clinical practice and research.
Læs mere Tjek på PubMedKonner CoolNatasha N. GaudreaultJessie D. TrujilloIgor MorozovChester D. McDowellDashzeveg BoldTaeyong KwonVelmurugan BalaramanPatricia AssatoDaniel W. MaddenEmily MantloJayme Souza-NetoFranco Matias-FerreyraJaime RetallickGagandeep SinghMichael SchotsaertMariano CarossinoUdeni B. R. BalasuriyaWilliam C. WilsonRoman M. PogranichniyAdolfo García-SastreJuergen A. Richta Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS, USAb Louisiana Animal Disease Diagnostic Laboratory and Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USAc Foreign Arthropod-Borne Animal Diseases Research Unit, National Bio and Agro-Defense Facility, United States Department of Agriculture, Manhattan, KS, USAd Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USAe Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAf Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USAg The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAh Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Emerg Microbes Infect, 31.12.2023
Tilføjet 31.12.2023
Clinical Infectious Diseases, 31.12.2023
Tilføjet 31.12.2023
Nirmatrelvir/ritonavirOmicronSARS-CoV-2COVID-19chronic kidney diseasehemodialysispharmacokinetics
Læs mere Tjek på PubMedHongqin XuHongyan LiHailong YouPeng ZhangNan LiNan JiangYang CaoLing QinGuixiang QinHongbo QuHeyuan WangBo ZouXia HeDan LiHuazhong ZhaoGang HuangYang LiHefeng ZhangLiping ZhuHongmei QiaoHongjun LiShurong LiuLina GuGuidong YinYe HuSongbai XuWeiying GuoNanya WangChaoying LiuPujun GaoJie CaoYang ZhengKaiyu ZhangYang WangHui ChenJian ZhangDongmei MuJunqi Niua Department of Hepatology, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, People’s Republic of Chinab Nursing Department, The First Hospital of Jilin University, Changchun, People’s Republic of Chinac Department of Pediatrics, First Hospital of Jilin University, Changchun, People’s Republic of Chinad Department of Infectious Diseases, Center of Infectious Diseases and Pathogen Biology, The First Hospital of Jilin University, Changchun, People’s Republic of Chinae Intensive Care Unit, The First Hospital of Jilin University, Changchun, People’s Republic of Chinaf Department of Infectious Diseases, Changchun Infectious Disease Hospital, Changchun, People’s Republic of Chinag Department of obstetrics and gynecology, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of Chinah Department of Cardiovascular Medicine, The First Hospital of Jilin University, Changchun, People’s Republic of Chinai Center of Tubercular Meningitis, Changchun Infectious Disease Hospital, Changchun, People’s Republic of Chinaj Department of Medical Affairs, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of Chinak Department of Endocrinology and Metabolism, The First Hospital of Jilin University, Changchun, People’s Republic of Chinal Department of Medical Affairs, Changchun Infectious Disease Hospital, Changchun, People’s Republic of Chinam Nursing Department, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of Chinan Department of Respiratory Medicine, The First Hospital of Jilin University, Changchun, People’s Republic of Chinao Department of Integrated Traditional and Western Medicine, Changchun Infectious Disease Hospital, Changchun, People’s Republic of Chinap Center of Information and Statistics, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of Chinaq Department of Integrated Traditional and Western Medicine, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of Chinar Department of pediatric respiratory medicine, The First Hospital of Jilin University, Changchun, People’s Republic of Chinas The Fifth treatment area, Changchun Infectious Disease Hospital, Changchun, People’s Republic of Chinat Department of Hepatology, Hepatobiliary Hospital of Jilin, Changchun, People’s Republic of Chinau Department of cerebral surgery, Changchun Infectious Disease Hospital, Changchun, People’s Republic of Chinav Department of Neurosurgery, the First Hospital of Jilin University, Changchun, People’s Republic of Chinaw Cancer Center, The First Hospital of Jilin University, Changchun, People’s Republic of Chinax Department of Neology, The First Hospital of Jilin University, Changchun, People’s Republic of Chinay Department of Clinical Epidemiology, The First Hospital of Jilin University, Changchun, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
Qianhui WuHongyu WangJianpeng CaiJingwen AiYang LiHaocheng ZhangSen WangFeng SunYanpeng WuJiaxin ZhouYan WangHongjie YuWenhong Zhanga School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, People’s Republic of Chinab Department of Infectious Disease of Huashan Hospital, National Medical Center for Infectious Diseases and Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Fudan University, Shanghai, People’s Republic of Chinac Key Laboratory of Medical Molecular Virology (MOE/MOH) and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of Chinad State Key Laboratory of Genetic Engineering, School of Life Science, Fudan University, Shanghai, People’s Republic of Chinae National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
John Paul CauchiAusra DziugyteMaria-Louise BorgTanya MelilloGraziella ZahraChristopher BarbaraJorgen SounessSteve AgiusNeville CallejaCharmaine GauciPauline VassalloJoaquin Barucha Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Maltab Molecular Diagnostics Pathology Department, Mater Dei Hospital, Msida, Maltac Mater Dei Hospital, Msida, Maltad Health Information and Research, Msida, Maltae Ministry for Health, Superintendent of Public Health, Msida, Maltaf EPIET Programme, European Centre for Disease Prevention and Control, Solna, Sweden
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
Paskorn SritipsukhoThana KhawcharoenpornBoonying SiribumrungwongPansachee DamronglerdNuntra SuwantaratAraya SatdhabudhaChanapai ChaiyakulsilPhakatip SinlapamongkolkulAuchara TangsathapornpongPornumpa BunjoungmaneeSira NanthapisalChamnan TanprasertkulNaiyana SritipsukhoChatchai MingmalairakAnucha ApisarnthanarakPichaya Tantiyavaronga Center of Excellence in Applied Epidemiology, Thammasat University, Pathumthani, Thailandb Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathumthani, Thailandc Department of Internal Medicine, Faculty of Medicine, Thammasat University, Pathumthani, Thailandd Department of Surgery, Faculty of Medicine, Thammasat University, Pathumthani, Thailande Department of Internal Medicine, Chulabhorn International College of Medicine, Thammasat University, Pathumthani, Thailandf Department of Obstetrics & Gynecology, Faculty of Medicine, Thammasat University, Pathumthani, Thailandg Thammasat Postdoctoral Fellowship, Thammasat University, Pathumthani, Thailandh Department of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathumthani, Thailand
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
Vincent Ka Chun YanFranco Wing Tak ChengCeline Sze Ling ChuiFrancisco Tsz Tsun LaiCarlos King Ho WongXue LiEric Yuk Fai WanJoshua Sung Chih WongEsther Wai Yin ChanIan Chi Kei WongMike Yat Wah KwanPatrick Ipa Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of Chinab School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of Chinac School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of Chinad Laboratory of Data Discovery for Health (D24H), , Hong Kong Science and Technology Park, Sha Tin, Hong Kong, People’s Republic of Chinae Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of Chinaf Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of Chinag Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong, People’s Republic of Chinah Aston Pharmacy School, Aston University, Birmingham, UKi Department of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, People's Republic of Chinaj Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
Can LiWenchen SongJasper Fuk-Woo ChanYanxia ChenFeifei LiuZhanhong YeAlvin Hiu-Chung LamJianpiao CaiAndrew Chak-Yiu LeeBosco Ho-Yin WongHin ChuDavid Christopher LungSiddharth SridharHonglin ChenAnna Jin-Xia ZhangKwok-Yung Yuena State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of Chinab Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Shatin, Hong Kong Special Administrative Region, People’s Republic of Chinac Department of Infectious Disease and Microbiology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, People’s Republic of Chinad Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of Chinae Academician Workstation of Hainan Province, Hainan Medical University – The University of Hong Kong Joint Laboratory of Tropical Infectious Diseases, Haikou, People’s Republic of Chinaf Department of Pathology, Hong Kong Children’s Hospital, Hong Kong Special Administrative Region, Hongkong, People’s Republic of Chinag Department of Pathology, Queen Elizabeth Hospital, Hong Kong Special Administrative Region, Hongkong, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
Ling QinXinmin DuanJay Zengjun DongYue ChangYang HanYan LiWei JiangHongwei FanXiufeng HouWei CaoHuadong ZhuTaisheng Lia Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of Chinab School of Clinical Medicine, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of Chinac KP Medical Partners Ltd, Taizhou, People's Republic of Chinad Emergency Department, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of Chinae State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of Chinaf Medical Intensive Care Unit, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, People’s Republic of Chinag Tsinghua University Medical College, Beijing, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
Miao WangBing ZhouQing FanXinrong ZhouXuejiao LiaoJingyan LinZhenghua MaJingke DongHaiyan WangXiangyang GeBin JuZheng Zhanga Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, People’s Republic of Chinab Guangdong Key Laboratory for Anti-infection Drug Quality Evaluation, Shenzhen, People’s Republic of Chinac Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, People’s Republic of China
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
K.L. BrownA. CeciC. RobyR. BriggsD. ZioloR. KorbaR. MejiaS.T. KellyD. ToneyM.J. FriedlanderC.V. Finkielsteina Virginia Tech Carilion School of Medicine, Virginia Tech, Roanoke, VA, USAb Molecular Diagnostics Laboratory, Fralin Biomedical Research Institute at VTC, Virginia Tech, Roanoke, VA, USAc Integrated Cellular Responses Laboratory, Fralin Biomedical Research Institute at VTC, Virginia Tech, Roanoke, VA, USAd Fralin Biomedical Research Institute at VTC, Virginia Tech, Roanoke, VA, USAe Department of Biological Sciences, Virginia Tech, Blacksburg, VA, USAf ZC Lab Services, Greenacreas, FL, USAg Molecular Detection and Characterization, Department of General Services, Division of Consolidated Laboratory Services, Richmond, VA, USAh Center for Zoonotic and Arthropod-borne Pathogens, Virginia Tech, Blacksburg, VA, USA
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
Hongjie XiaJason YeungBirte KalveramCody J. BillsJohn Yun-Chung ChenChaitanya KurhadeJing ZouSteven G. WidenBrian R. MannRebecca KondorC. Todd DavisBin ZhouDavid E. WentworthXuping XiePei-Yong Shia Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USAb Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USAc Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USAd Institute for Human Infection and Immunity, University of Texas Medical Branch, Galveston, TX, USAe Sealy, Institute for Drug Discovery, University of Texas Medical Branch, Galveston, TX, USAf Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USAg Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USAh Sealy Center for Structural Biology & Molecular Biophysics, University of Texas Medical Branch, Galveston, TX, USA
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023
Marc-Antoine de La VegaEfstathia PolychronopoulouAra XIIIZhe DingTong ChenQixing LiuJiaming LanMarie-Edith Nepveu-TraversyHugues Fausther-BovendoMohammed F. ZaidanGary WongGulshan SharmaGary P. Kobingera Galveston National Laboratory, Department of Microbiology and Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USAb Office of Biostatistics, University of Texas Medical Branch, Galveston, TX, USAc Viral Hemorrhagic Fevers Research Unit, CAS Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, People’s Republic of Chinad University of Chinese Academy of Sciences, Beijing, People’s Republic of Chinae Global Urgent and Advanced Research and Development (GuardRX), Batiscan, Canadaf Department of Internal Medicine, Division of Pulmonary, Critical Care, & Sleep Medicine, University of Texas Medical Branch, Galveston, TX, USAg Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
Emerg Microbes Infect, 30.12.2023
Tilføjet 30.12.2023